Pharmacology

The Skinny on Hoodia

May 16, 2008
The Skinny on Hoodia

Commentary by Melissa Freeman, PGY-2 

As summertime is just around the corner, many begin to evaluate whether their bodies are ready to expose what has been hidden under those bulky winter clothes. Between busy lives and an innate desire for quick results, people sometimes turn to over-the-counter diet pills for a slimmer physique. With recently banned products like Ephedra, consumers are looking for newer, more promising weight loss products. During a recent clinic visit, a patient asked me about my thoughts on diet pills that …

Read more »

Class Act: The Polypill Panacea

May 1, 2008
Class Act: The Polypill Panacea

Commentary by David Hatcher, MSIII (reviewed by Neil Shapiro, MD Editor-In-Chief, Clinical Correlations)

C.M. is a 68 year-old retired Caucasian male with a past medical history significant for coronary artery disease, hyperlipidemia, HTN, and a 30 pack year history of smoking. His drug regimen consists of a beta-blocker, an ace inhibitor, a statin, and aspirin.

Patients like C.M. are now more common than ever before. He has already had one heart attack, and he has multiple risk factors for another, many of them preventable. In …

Read more »

Future Medicine: The Search for a New Anticoagulant

April 16, 2008
Future Medicine: The Search for a New Anticoagulant

Future Medicine is a new section of Clinical Correlations devoted to hot areas of research and development in various fields of medicine. In tihis series, we will highlight treatments in their infancy, from basic research opening up new targets for treatment, to following small molecules throughout their clinical investigation. We will also bring you the latest on technology and devices, as well as perspectives on drug discovery from a business point of view. Watch out – the future is just around the corner!

Commentary by

Read more »

Class Act: Do Statins Always Have to Be Taken in the Evening?

January 10, 2008
Class Act: Do Statins Always Have to Be Taken in the Evening?

Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our students in the clinics or on the wards. Prior to publication, each commentary is thoroughly reviewed for content by a faculty member. Enjoy…

Commentary by David Leaf, MSIV

HMG-CoA reductase inhibitors (statins) are the most powerful drugs used for lowering LDL cholesterol, with median reductions in the range of 30 to 63 …

Read more »

Clinical Question: Pharmacology

December 28, 2007
Clinical Question: Pharmacology

Is there evidence to support the use of Lantus® (human insulin analog glargine) administered Q12h in Type 1 Diabetes?

Commentary by Kathy Lee, Pharmacy Resident 

The goal of diabetes management is to reduce the risk of long-term complications by maintaining near-normal glycemic control, in addition to reducing other risk factors. Patients with type 1 diabetes have an absolute deficiency in insulin and require exogenous insulin replacement. Lantus®, human insulin analog glargine, is the only long-acting insulin that exhibits a “peakless” action profile with duration of …

Read more »

FDA Warns of Possible Link Between Chantix Therapy and Mood Disturbances

December 14, 2007
FDA Warns of Possible Link Between Chantix Therapy and Mood Disturbances

Commentary by Robert Leonard PharmD, Pharmacy Resident New York Harbor Healthcare System

On November 20, 2007 the FDA announced mounting evidence linking varenicline (Chantix®) therapy for smoking cessation with suicidal ideation and erratic and aggressive behavior. The announcement comes in response to post-marketing case reports submitted to the FDA by the makers of Chantix®, Pfizer Inc. Early review of the cases reveal new onset of depressed mood, suicidal thoughts, and changes in emotions or behaviors within days to weeks of starting Chantix® therapy. A direct …

Read more »

FDA Approves Raltegravir- A First in New Class of HIV Medications

November 14, 2007
FDA Approves Raltegravir- A First in New Class of HIV Medications

Commentary by Helen Kourlas PharmD, Pharmacology Section Editor

On October 16th the FDA announced the approval of raltegravir (Isentress®) for the treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents. The use of raltegravir is recommended for patients who have HIV-1 strains resistant to multiple antiretroviral medications. Raltegravir belongs to a new pharmacologic class of antiretrovirals called HIV integrase strand transfer inhibitors. Integrase is one of the three enzymes necessary for the HIV-1 virus to replicate, and integrase inhibitors can stop …

Read more »

FDA Approves Label Revision for Erectile Dysfunction Drugs

October 24, 2007
FDA Approves Label Revision for Erectile Dysfunction Drugs

Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident

On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) inhibitors. This includes drugs Cialis®, Levitra®, Viagra®, as well as Revatio®, a PDE-5 inhibitor indicated for pulmonary arterial hypertension (PAH). The label revisions draw attention to the potential risk of sudden hearing loss, sometimes associated with vestibular symptoms such as tinnitus, vertigo, and dizziness. Based on 29 postmarketing reports of this …

Read more »